Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis
Combination chemotherapy for advanced hepatocellular carcinoma complicated by major portal vein thrombosis
复制标题
DOI：
10.1159/000048279
复制
发表时间：
2002-01-01
期刊：
影响因子：
3.5
通讯作者：
Kobayashi, K
中科院分区：
文献类型：
--
作者：
Kaneko, S;Urabe, T;Kobayashi, K
晚期肝细胞癌（HCC）患者预后不良，有必要开发新的治疗策略。在这里，我们报告了联合化疗在生化调节中的功效。 Huh7 细胞中证实了干扰素 α-2b 对 5-氟尿嘧啶或顺铂的协同作用。甲氨蝶呤-5-氟尿嘧啶、顺铂和干扰素-a-2b 联合治疗的疗效在 34 例 HCC 并发主要门静脉血栓患者中得到证实。在符合研究资格的 29 名患者中，有 3 名完全缓解者和 10 名部分缓解者，总体缓解率为 45%。 34 名患者的 2 年生存率为 15%，完全缓解和部分缓解者的中位生存期为 11 个月。存在严重的短暂血液毒性。 8名患者患有肾功能不全，其中4人接受了血液透析。尽管对照研究显然是必要的，但我们的联合疗法在晚期 HCC 患者中引起了良好的反应。根据我们的结果，对于并发主要门静脉侵犯的晚期 HCC，应尝试强化化疗。版权所有 (C) 2002 S. Karger AG，巴塞尔。
Patients with advanced hepatocellular carcinoma (HCC) have a poor prognosis, and the development of new therapeutic strategies is necessary. Here we report the efficacy of combination chemotherapy in our biochemical modulation. Synergistic effects of interferon-alpha-2b on 5-fluorouracil or cisplatin were demonstrated in Huh7 cells. The efficacy of methotrexate-5-fluorouracil, cisplatin, and interferon-a-2b combination therapy was demonstrated in 34 patients with HCC complicated by major portal vein thrombosis. Among the 29 patients eligible for the study, there were 3 complete responders and 10 partial responders with an overall response rate of 45%. The 2-year survival of the 34 patients was 15%, and the median survival of complete and partial responders was 11 months. There was severe transient hematological toxicity. Eight patients suffered from renal insufficiency, and 4 of them underwent hemodialysis. Although a control study is clearly necessary, our combination therapy induced a good response in the patients with advanced HCC. On the basis of our results, intensive chemotherapy should be attempted in advanced HCC complicated by major portal vein invasion. Copyright (C) 2002 S. Karger AG, Basel.